Antibody-drug conjugates are currently being investigated in more than 260 clinical trials.“It’s going to be the next novel ...

Daiichi Sankyo and AstraZeneca entered into a global collaboration to jointly develop and commercialize ENHERTU (a HER2 directed ADC) in March 2019, and DS-1062 (a TROP2 directed ADC) in July 2020 ...

AstraZeneca (NASDAQ:AZN) and Daiichi Sankyo (OTCPK:DSNKY) announced Wednesday that Enhertu, their jointly developed antibody-drug conjugate, reached the main goal in a Phase 3 trial in certain ...

Pascal Soriot's comments came during AstraZeneca's Q2 earnings call in regard to President Donald Trump’s newly announced ...

AstraZeneca, Daiichi Sankyo announce BTD for datopotamab deruxtecan December 09, 2024 — 05:30 am EST Written by TheFly for TipRanks -> ...

(RTTNews) - British drug maker AstraZeneca Plc (AZN.L, AZN) and Daiichi Sankyo (DSKYF.PK) announced Monday that their Datroway (datopotamab deruxtecan) has been approved in the United States for ...

Daiichi Sankyo has been particularly active in this field, and the company’s collaborations including the one with AstraZeneca, have led to the development of successful drugs like Enhertu ...

Following the U.S. approval, $45 million is due from AstraZeneca to Daiichi Sankyo Co., Ltd. DSKYF DSNKY as a milestone payment for the locally advanced or metastatic EGFR-mutated NSCLC indication.

AstraZeneca and Daiichi Sankyo's Datroway Approved to Treat Non-Small Cell Lung Cancer in U.S. Provided by Dow Jones Jun 23, 2025, 11:33:00 PM ...

Daiichi Sankyo (DSNKY) and AstraZeneca’s (AZN) Enhertu has been approved in the European Union as a monotherapy for the treatment of adult patients with unresectable or metastatic hormone ...

AstraZeneca (AZN) stock in focus as its partner Daiichi Sankyo (DSNKY) wins EU backing for their jointly developed breast cancer drug Dato-DXd. Read more here.

Overview DSKYF Daiichi Sankyo Co Ltd $25.10 6.81 % DSNKY Daiichi Sankyo Co Ltd $24.21 -1.57 % On Monday, the U.S. Food and Drug Administration (FDA) approved AstraZeneca plc and Daiichi Sankyo’s ...